Real world assessment for Sofosbuvir + Velpatasvir therapy for decompensated cirrhotic patients with HCV

Real world assessment for Sofosbuvir + Velpatasvir therapy for decompensated cirrhotic patients with HCV - Sofvel study-1

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000037258

Enrollment

Registered

2024-03-31

Start date

2019-03-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Decompensated cirrhotic patients with HCV

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Decompensated hepatic cirrhosis with HCV; Child-Pugh Score; 7-12)

Exclusion criteria

Exclusion criteria: Active Hepatocelluar Carcinoma Renal impairment; eGFR <30ml/min/1.73m2 Allergy to Sofosbuvir or Velpatasvir

Design outcomes

Primary

Measure	Time frame
Sustained viral response at 12 week	—

Countries

Japan

Contacts

Public ContactAkihiro Tamori

Osaka City University Graduate School of Medicine Department of Hepatology

atamori@med.osaka-cu.ac.jp06-6645-3905

Outcome results